ImmunityBio Advances Pipeline with Novel Lymphoma Trial
Published on 02/03/2026 at 21:44 | Redaktion boerse-global.de
ImmunityBio has initiated a new clinical study, marking a strategic expansion of its development pipeline. The U.S. biotechnology firm announced the launch of a Phase 2 trial evaluating an experimental cell therapy combination for a specific group of lymphoma patients, notably without the use of chemotherapy. This move tests whether the company’s therapeutic platform can succeed beyond its established bladder cancer indication.
On February 2, 2026, ImmunityBio publicly disclosed the commencement of its ResQ215B study. The trial will enroll patients diagnosed with indolent B-cell non-Hodgkin lymphoma (iNHL), a category of slow-growing lymphatic cancers.
The investigational regimen is a three-part combination therapy:
- CD19 t-haNK: An Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
